Stereotactic body radiation therapy for early-stage lung cancer: Are we "all In"

Journal of Thoracic Oncology

Volumn 5, Issue 7, 2010, Pages 927-929

  Bogart, Jeffrey A ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUORODEOXYGLUCOSE;

BRACHYTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER RELAPSE; CANCER SURGERY; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMORBIDITY; DIABETES MELLITUS; EARLY CANCER; EDITORIAL; HIGH RISK PATIENT; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TOXICITY; OVERALL SURVIVAL; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOFREQUENCY ABLATION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; CANCER STAGING; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS; RADIOSURGERY;

HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RADIOSURGERY;

EID: 77954418914     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e3a319     Document Type: Editorial

References (21)

1. Chi A, Liao Z, Nguyen NP, et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol 2010;94: 1-11.
2. Siva S, MacManus M, Ball D. Review of stereotactic RT for pulmonary oligometastases. Stereotactic radiotherapy for pulmonary oligometasta-ses\a systematic review. J Thorac Oncol In press.
3. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
4. Timmerman R, Galvin J, Michalski J, et al. Accreditation and quality assurance for Radiation Therapy Oncology Group: multicenter clinical trials using stereotactic body radiation therapy in lung cancer. Acta Oncol 2006;45:779-786. (Pubitemid 44423122)
5. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-4839. (Pubitemid 46630909)
6. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int JRadiat Oncol Biol Phys 2009;5:677-682.
7. Paludan M, Traberg Hansen A, Petersen J, et al. Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: is there a dose-volume dependency? Acta Oncologica 2006;45:818-822. (Pubitemid 44423127)
8. Shennib H, Bogart J, Herndon JE, et al. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. J Thorac Cardiovasc Surg 2005; 129:813-818. (Pubitemid 40487882)
9. Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 2007; 243:268-275. (Pubitemid 46579719)
10. Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving >39 GY predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int JRadiat Oncol Biol Phys 2010;76: 796-801.
11. Voroney JP, Hope A, Dahele MR, et al. Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. J Thorac Oncol 2009;4:1035-1037.
12. Pettersson N, Nyman J, Johansson KA. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose-and volume-response analysis. Radiother Oncol 2009;91:360-368.
13. Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009;93:408-413.
14. Phase II study of stereotactic body radiotherapy in patients with resectable stage I or II non-small cell lung cancer. Available at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid = 571744& version=HealthProfessional&protocolsearchid=759745. Accessed April 17, 2010.
15. Ettinger D, Ackerly W, Bepler G, et al. NCCN practice guidelines in oncology: non-small cell lung cancer. Available at: http://www.nccn. org/professionals/physiciangls/PDF/nscl.pdf. Accessed April 17, 2010.
16. Devisetty K, Salama J. Tumor necrosis and cavitation following stereotactic body radiation therapy. J Thorac Oncol In press.
17. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-1412.
18. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-48.
19. Phase III randomized study of sublobar resection with versus without intraoperative brachytherapy in high-risk patients with stage I non-small cell lung cancer. Available at:http://www.cancer.gov/search/ViewClinicalTrials.aspx? cdrid=422346&version=HealthProfessional&protocolsearchid=5691197. Accessed April 5, 2010.
20. Bogart JA, Hodgson L, Seagren SL, et al. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol 2010;28:202-206.
21. Phase II study of accelerated hypofractionated 3-dimensional conformal radiotherapy in patients with inoperable stage I or II non-small cell lung cancer. Available at: http://www.cancer.gov/search/ViewClinicalTrials. aspx?cdrid=486919&version=HealthProfessional&protocolsearchid= 5691106. Accessed April 5, 2010.